Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ABVC BIOPHARMA, INC. (ABVC)

ABVC BioPharma closes $4.1 million note sale, settles Lind claim for $625,000

Negative Impact 4 of 5 financing Written later

On October 30, 2026, ABVC BioPharma sold senior convertible notes with $4,106,060 in principal for a purchase price of $3,387,500, maturing June 30, 2027. The company also agreed on October 26 to pay Lind $625,000 to settle a New York lawsuit and retire its earlier Lind notes, while Lind's warrant rises by 20%. Because the notes convert into common stock at a discount, shareholders may face dilution.

Key points

  • Notes: $4,106,060 principal, $3,387,500 purchase price, 17.5% original issue discount, maturity June 30, 2027
  • Conversion at 85% of the average of three VWAPs, with a $0.2 floor price; issuance capped at 19.99% of shares outstanding unless shareholders approve by June 30, 2027
  • Lind settlement: $625,000 payment; Lind warrant for 398,000 shares increases 20%
  • Special meeting on October 28, 2026: all three proposals approved, including the 2026 Equity Incentive Plan with 92.83% For

The filing

CompanyABVC BIOPHARMA, INC. (ABVC)
Form8-K, current report
Filed with the SECNov 2, 2026, 9:51 AM ET
Accession number0001213900-26-114729

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale5.07 Shareholder Vote Results7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.